Scribe Therapeutics

We’re excited to present at the American Heart Association’s Scientific Sessions for the first time, reporting new preclinical data that demonstrate the potential of our CRISPR genome and epigenome editing technologies for addressing #CardiometabolicDisease. Learn about our four presentations, including a late-breaking talk, below and in our press release: https://lnkd.in/gAk6KNWR 📅 November 15-18, 2024 🧑🔬 Aarif Khakoo, Christopher Duncan-Lewis, PhD, Santhosh Karanth PhD, Elena Smekalova, Maria Mirotsou  📣 A Novel CRISPR-based Epigenetic Silencer Potently, Durably, and Safely Reduces LDLc in Non-Human Primates at Therapeutically Relevant Doses 📣 Engineering and Development of Optimal CRISPR Based Genome Modification Molecules for Safe and Effective LDL-C Lowering 📣 A Single-Dose of a Novel CasX-Editor Lowers APOC3 Levels In Vivo #AHA24 #CRISPR #CRISPRbyDesign #GeneEditing #Epigenetics #EpigeneticEditing

Congratulations to our CEO Benjamin Oakes for being named to the PharmaVoice 100 industry leaders reshaping biopharma! Read more about his journey, insights, and ongoing contributions engineering novel #CRISPR-based genetic medicines as a pioneer in the field of cell and gene therapy: https://ow.ly/S6jq50THm29 #PV100 #PharmaVoice100 #CRISPRbyDesign #GeneEditing #MolecularEngineering #Biotech

Meet our Executive Team at #CGMesa24 in Phoenix! At this year’s Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa, Scribe CEO Benjamin Oakes will be presenting our work creating in vivo #CRISPR-based therapies to empower patients to rewrite their genetic destiny. Check it out on Wednesday, Oct. 9 at 10:30am MST in FLW Ballroom F, and meet our CBO Svetlana Lucas and CFO David Parrot as well. More details: https://ow.ly/iQK550TGhlf #CRISPRbyDesign #GeneEditing #EpigeneticEditing #MolecularEngineering #Biotech

The newly designated National #SickleCell Awareness Month is an important reminder that millions of people worldwide are living with the debilitating condition and critically need treatments. Swipe right ➡️ to learn more about sickle cell disease (SCD), how you can support patients, and the global effort to develop novel therapies. #SickleCellMatters #CRISPR #CRISPRbyDesign #GeneEditing #MolecularEngineering #Biotech

Take action this #WorldHeartDay to support millions of people affected by cardiovascular disease (CVD). To overcome challenges with existing treatments like adherence, we are engineering safe, effective #CRISPR-based genetic medicines for CVD patients in need. Read more about our first program in Scrip Citeline: https://lnkd.in/gTRp6mQa #CRISPR #CRISPRbyDesign #GeneEditing #MolecularEngineering #Biotech

On the latest episode of the Progress, Potential, And Possibilities podcast, our CEO Benjamin Oakes joins host Ira S. Pastor to share his journey and mission to engineer the future of genetic medicine. They discuss his work building genome editing tools prior to the discovery of #CRISPR, the moment of clarity when Scribe co-founder Jennifer Doudna’s seminal paper published in 2012, launching Scribe to engineer genome and epigenome editing tools that are fit for purpose, and more. 🎧 To learn about our progress developing in vivo CRISPR-based therapeutics, give the podcast a listen: https://lnkd.in/gujW7h_p #GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine #Biotech

Meet our management team, including CEO Benjamin Oakes, CBO Svetlana Lucas, and CFO David Parrot, at upcoming conferences: 1️⃣ Cantor Global Healthcare Conference (Sept. 19 in New York) 2️⃣ BofA Healthcare Trailblazers Private Company conference (Sept. 25 in Boston) 3️⃣ Meeting on the Mesa (corporate presentation on Oct. 9 in Phoenix) They will be available for one-on-one meetings at each event. For more details, read our press release: https://lnkd.in/gWQ3JaCk Alliance for Regenerative Medicine Cantor Fitzgerald Bank of America #CRISPR #CRISPRbyDesign #GeneEditing #MolecularEngineering #Biotech #EpigenomeEditing

Big Think interviewed our co-founder and CEO Benjamin Oakes about his philosophy on leadership, innovation, and human endeavor. Editor Mike Hodgkinson writes that “if you lead (or belong to) a mission-driven team in any company, in any arena … you’ll find [Oakes’s] insights as finessed and meticulously engineered as the Scribe technologies he hopes will ‘rewrite the story of disease.’” Read the full interview covering radical innovation in #CRISPR and #biotech, skills that translate from academia to industry, and more: https://ow.ly/HJ9g50Tjuet #GeneEditing #EpigeneticEditing #CRISPRbyDesign #MolecularEngineering #GeneticMedicine

Epigenome editing can silence a target gene instead of permanently editing the genome, says our CEO Benjamin Oakes, which could open new doors to developing critical genetic medicines. Learn how we’re adding epigenome editing capabilities to our #CRISPR toolbox from this recent Aspen Ideas panel: https://ow.ly/QGoV50TfCIL The Aspen Institute #CRISPRbyDesign #GeneEditing #EpigeneticEditing #GeneticMedicine

Another summer, another annual beach day enjoyed with our Scribe family and friends! #NationalBeachDay #BayAreaBiotech